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Efficient Human Cytomegalovirus Reactivation Is Maturation
Dependent in the Langerhans Dendritic Cell Lineage and Can Be
Studied using a CD14 Experimental Latency Model
Margaret M. Huang,a Verity G. Kew,a Kevin Jestice,b Mark R. Wills,a and Matthew B. Reevesa
Departments of Medicinea and Clinical Haematology,b University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom
Studies from a number of laboratories have shown that the myeloid lineage is prominent in human cytomegalovirus (HCMV)
latency, reactivation, dissemination, and pathogenesis. Existing as a latent infection in CD34 progenitors and circulating
CD14 monocytes, reactivation is observed upon differentiation to mature macrophage or dendritic cell (DC) phenotypes.
Langerhans’ cells (LCs) are a subset of periphery resident DCs that represent a DC population likely to encounter HCMV early
during primary infection. Furthermore, we have previously shown that CD34 derived LCs are a site of HCMV reactivation ex
vivo. Accordingly, we have utilized healthy-donor CD34 cells to study latency and reactivation of HCMV in LCs. However, the
increasing difficulty acquiring healthy-donor CD34 cells—particularly from seropositive donors due to the screening regimens
used—led us to investigate the use of CD14 monocytes to generate LCs. We show here that CD14 monocytes cultured with
transforming growth factor  generate Langerin-positive DCs (MoLCs). Consistent with observations using CD34 derived LCs,
only mature MoLCs were permissive for HCMV infection. The lytic infection of mature MoLCs is productive and results in a
marked inhibition in the capacity of these cells to promote T cell proliferation. Pertinently, differentiation of experimentally
latent monocytes to the MoLC phenotype promotes reactivation in a maturation and interleukin-6 (IL-6)-dependent manner.
Intriguingly, however, IL-6-mediated effects were restricted to mature LCs, in contrast to observations with classical CD14 de-
rived DCs. Consequently, elucidation of the molecular basis behind the differential response of the two DC subsets should fur-
ther our understanding of the fundamental mechanisms important for reactivation.
Human cytomegalovirus (HCMV) represents an opportunisticpathogen that is a major cause of disease in a number of
immunocompromised patient populations (30, 60). A significant
contribution to morbidity in the clinical setting results from the
reactivation of latent HCMV, particularly in seropositive bone
marrow transplant recipients (40). Although themechanisms that
govern HCMV reactivation have not been fully elucidated, work
from a number of laboratories has shown that CD34 hematopoi-
etic cells, and the early granulocyte-macrophage progenitors de-
rived from them, which are normally resident in the bonemarrow
are an important site for the carriage ofHCMV latency in vivo (27,
34, 53) and that reactivation is intrinsically linked with the differ-
entiation to amorematuremyeloid cell phenotype (19, 37, 45, 56,
59, 64).
Langerhans’ cells (LCs) are a unique population of dendritic
cells (DCs) resident in the epidermis and a number of mucosal
tissues (e.g., nasal, oral, vaginal, and corneal). They are derived
from bone marrow progenitors (26) and exhibit a capacity for
self-renewal (11, 36), as well as exhibiting prodigious longevity for
aDC,with a half-life of up to 78 days documented (62) and, in one
case, a donor’s LCs were observed to persist in the recipient for
more than 12 months after a skin graft procedure (23). Their
generation (and/or survival) both in vitro and in vivo is acutely
dependent on transforming growth factor  (TGF-) (4, 25,
57)—TGF- knockout mice do not possess LCs—and can be
characterized by their (almost) unique expression of the lectin
molecule, Langerin (CD207) (6, 15, 42, 61), along with the coex-
pression of cutaneous leukocyte antigen, E-Cadherin, and class II
major histocompatibility complex (MHC) molecules, as well as
intracellular Birkbeck granules (reviewed in reference 35). LCs
were classically described as potent activators of T cell immunity
(50); however, more recent studies with cytolytic viruses argue
that the ability of skin resident DCs to respond is subverted spe-
cifically by cytolytic viruses and that the major immune response
is mediated by cross-presentation by other DC subtypes (2, 5, 21).
In vitro, Langerhans-like cells can be generated from CD34
cells (CD34 derived LCs) under certain cell culture conditions,
the study of which has been used to ascribe potential LC functions
(9, 52, 57, 58). Thus, in the context of infection, it was hypothe-
sized that LCs existing in the periphery encountered infectious
agents at epithelial surfaces and represent the first line of defense,
which, in part, would involve the activation of a profound CD8
cytotoxic response. Although murine studies suggest that the re-
ality may be more complex than this (for example, cytolytic vi-
ruses induce LC apoptosis, and thus the antigen presentation is
mediated by a blood-derivedCD8population ofDCs after apop-
tosis of the infected LCs [2]), it is well established that in humans
LCs have an important immunomodulatory role (24).
Studies of HCMV have utilized both CD34 and CD14 pro-
genitor cells to analyze the viral interaction withmyeloid DCs (22,
28, 29, 39, 45–47). Interestingly, the heterogeneity of the myeloid
DCpopulation is also evidenced by the biology of theseDCs in the
context of HCMV infection. In experimental studies, immature
and mature CD14 derived DCs (MoDCs) are similarly permis-
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sive for HCMV lytic infection (47). In contrast, CD34 derived
LCs were previously shown to have an absolute requirement for
CD40L-induced maturation for permissive infection (22). Thus,
an understanding of the molecular reasons for such differences
could impact on our understanding of the regulation of HCMV
infection and viral gene expression.
In our own studies of HCMV reactivation, we have relied on
both CD34 and CD14 derived DC model systems (43, 44, 46).
However, it is becoming ever more important to determine
whether observations made in experimental latency systems truly
reflect events that occur upon the reactivation of naturally latent
virus. In our own studies we have focused on the use of CD34
and CD14 cells for modeling HCMV latency. Our own experi-
ences have suggested that access to regular supplies of CD34
material is becoming increasingly difficult. In contrast, CD14
monocytes are readily available from healthy donors and are pres-
ent at much higher concentrations in the blood, and thus we hy-
pothesized that we could use MoLCs (MoLCs) as another model
for studying the interaction of HCMV with LCs. In the present
study, we show that MoLCs exhibit a number of functional simi-
larities with CD34 LCs regarding the biology of HCMV lytic and
latent infection and, pertinently, we have revealed intriguing dif-
ferences between myeloid DC subsets regarding the biology of
HCMV reactivation impacting directly on our understanding of
HCMV reactivation from latency.
MATERIALS AND METHODS
Ethical statement. All research describing studies on primary humanma-
terial with HCMV were assessed and approved by the Cambridge Local
Research Ethics committee. Informed consent was given for the collection
of venous blood samples from healthy donors or leukophoresis products
from granulocyte-colony-stimulating factor mobilized patients and was
performed in accordance with established guidelines for the handling
and processing of said tissue by the Cambridge Local Research Ethics
committee.
Cells and tissue culture. Human foreskin fibroblasts (HFFs) were
maintained in Eagle minimal essential medium containing 10% fetal calf
serum (EMEM-10; Sigma-Aldrich, Poole, United Kingdom) and incu-
bated at 37°C and in 5% CO2 according to the standard procedure for
tissue culture. CD14 mononuclear cells were directly isolated from
HCMV-seronegative blood, and immature DCs were generated as de-
scribed previously. Briefly, peripheral blood mononuclear cells were pre-
pared by centrifugation on a Ficoll-Hypaque (LymphoPrep; Takeda,
United Kingdom) density gradient. Magnetic-activated cell sorting using
CD14 antibody-conjugated MicroBeads (Miltenyi Biotec, Surrey,
United Kingdom) allowed collection of a CD14 mononuclear cell-en-
riched population, which weremaintained in X-VIVO 15 serum-freeme-
dium (Lonza, Walkersville, MD). To promote differentiation to an
MoDC phenotype, cultures were stimulated with interleukin-4 (IL-4; 100
ng/ml) and granulocyte-macrophage colony-stimulating factor (GM-
CSF; 100 ng/ml) for 6 days. Alternatively, the cultures were stimulated
with IL-4 (10 ng/ml), TGF- (10 ng/ml), and GM-CSF (100 ng/ml) for 2
days, themediumwas changed, and TGF- (10 ng/ml) andGM-CSF (100
ng/ml) were added for a further 4 days to induce differentiation into
immature MoLCs. Loosely adherent cells were collected by moderate
aspiration and transferred to fresh wells. Mature DCs and LCs were
generated by adding lipopolysaccharide (LPS) in fresh medium (500
ng/ml; Sigma-Aldrich). Alternatively, in studies that analyzed HCMV
reactivation, immature LCs (iLCs) were incubated with IL-6 or IL-8
(50 ng/ml) or were coincubated with LPS plus neutralizing antibodies
to IL-6, IL-8, or goat IgG isotype control (10 g/ml; R&D Systems,
Minneapolis, MN) in fresh medium. Unless stated otherwise, all cyto-
kines were from Peprotech EC.
Latency establishment and coculture experiments. First, to ensure
that propagated TB40/e and VR1814 strain retained tropism for myeloid
cells, all preparations were tested for their ability to infect retinal pigment
epithelial cell line andMoDCs prior to use in all studies ofHCMV latency.
The CD14monocytes were cultured for at least 4 h in X-VIVO 15 after
isolation and then infected with a preparation of the clinical isolate
TB40/e (multiplicity of infection [MOI] of 5). After 3 h, the infected cells
were washed and cultured in fresh X-VIVO 15medium for 7 days. After 7
days, medium was exchanged again, and fresh medium containing cyto-
kines that promote DC and LC differentiation were added as described
previously. Reactivation was measured by indirect immunofluorescence
for immediate-early (IE) gene expression at 24 h poststimulation of DCs.
Alternatively, virus production from reactivating mature MoDCs and
MoLCs was assayed after coculture on a confluent monolayer of HFFs
with samples of supernatant taken at regular intervals and used to inocu-
late freshHFFs to test for infectious virus by indirect immunofluorescence
staining.
Indirect immunofluorescence and Western blotting. Infected cells
were rinsed in phosphate-buffered saline (PBS) andfixed for 10min in 4%
paraformaldehyde at room temperature. After permeabilization with
0.1% Triton X-100 in PBS, the cells were incubated with monoclonal
mouse anti-IE antibody (Millipore) at a 1:1,000 dilution in PBS for 1 h at
room temperature. After being washed with PBS, the bound antibodies
were detected using Alexa Fluor 594 (Millipore, Billerica, MA)-conju-
gated goat anti-mouse immunoglobulins at a 1:1,000 dilution in PBS,
togetherwith nuclear stainHoechst at a 1:1,000 dilution in PBS in the dark
for 1 h at room temperature. After a washing step with PBS, the infected
cells were visualized using a Nikon immunofluorescence microscope and
quantified using ImagePro WCIF ImageJ software (National Institutes of
Health). The percent infection was calculated by dividing the number of
infected cells (red) by the total number of cells (blue) from at least four
fields of view.
Protein expression was detected by Western blotting of denatured
protein samples. To detect viral protein expression, mouse anti-IE anti-
body (1:500; Millipore) or mouse anti-gB antibody (1:500; Santa Cruz
Biotechnology, Santa Cruz, CA) was incubated at 4°C overnight with
nitrocellulose and incubated with a horseradish peroxidase (HRP)-con-
jugated goat anti-mouse secondary antibody (1:4,000; Santa Cruz Bio-
technology) for 1 h at room temperature. As a loading control, nitro-
cellulose filters were also incubated with a rabbit anti-GAPDH control
(1:1,000; Abcam, Cambridge, United Kingdom), followed by an
HRP-conjugated goat anti-rabbit antibody (1:4,000; Santa Cruz Biotech-
nology); both antibody incubations were performed at room temperature
for 1 h. The blots were processed using ECL Plus (GE Life Sciences,
Amersham,UnitedKingdom) and exposed toKodak autoradiograph film
(Sigma-Aldrich).
Nucleic acid isolation and analysis. Total RNA was extracted from
106 cells using an RNeasy kit as described by the manufacturer (Qiagen,
Sussex, United Kingdom). Residual genomic DNA was removed by
DNase I digestion (Promega, Madison, WI), followed by the production
of first-strand cDNA using the Promega RT system. Standard PCR was
carried out using 2 PCRMaster Mix (Promega) containing DNA poly-
merase, MgCl2, and deoxynucleoside triphosphates. Gene- and pro-
moter-specific primers were used to amplify target sequences by PCR
under the following cycling conditions: 95°C for 5 min, followed by 20 to
35 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min, and then
a final extension at 72°C for 10 min. IE72 was amplified with the sense
primer 5=-CATCCACATCTCCCGCTTAT-3= and the antisense primer
5=-CAC GAC GTT CCT GCA GAC TAT G-3=. The IE product size is 579
bp from DNA and 408 bp from cDNA. A 548-bp actin product was am-
plified using the sense primer 5=-GCT CCG GCA TGT GCA-3= and the
antisense primer 5=-AGGATC TTCATGAGGTAGT-3= under the same
PCR conditions.
For quantitative PCR, primers that amplified the IE region of HCMV
were used (31). The following reaction conditions were used in a 96-well
Huang et al.
8508 jvi.asm.org Journal of Virology
 o
n
 Septem
ber 12, 2012 by CAM
BRIDG
E UNIVERSITY LIBRARY
http://jvi.asm.org/
D
ow
nloaded from
 
plate format with the forward primer AGC GCC GCA TTG AGG A, the
reverse primer CAGACTCTCAGAGGATCGGCC, and the probe ATC
TGC ATG AAG GTC TTT GCC CAG TAC ATT (FAM probe with a
TAMRA quencher). PCRs were performed using TaqMan master mix
(Applied Biosystems, Foster City, CA) in a 7500HT machine (Applied
Biosystems). Actin was amplified using a VIC-actin commercial probe
(Applied Biosystems), and statistical analysis and interpretationwere per-
formed as described previously (49).
Cell surface phenotype flow cytometry analysis. A total of 105 cells
were pelleted at 400  g for 5 min and then resuspended in the residual
volume. The cells were incubated with 3 l of fluorescein isothiocyanate
(FITC)-conjugated mouse anti-human CD207, CD14, E-Cadherin, and
CD1a antibodies in the dark for 20min. The appropriatemouse IgG-FITC
antibody was used as an isotype control. Alternatively, cells were incu-
batedwith 3l of allophycocyanin (APC)-conjugatedmouse anti-human
CD83 or HLA-DR antibody or with the appropriate mouse IgG1-APC
isotype control. To detect class I expression, cells were incubated with a
mouse anti-human phycoerythrin (PE)-conjugated HLA-ABC antibody
or an appropriate isotype-matched control. After washing in 10 vol-
umes of PBS, the cells were pelleted at 400 g for 5 min and resuspended
in 500 l of phosphate-buffered saline (PBS) before analysis by flow cy-
tometry (BD FACSCalibur or BD FACSsort). The data handling was per-
formed using WinMDI2.9 software. All Antibodies were from BD Life
Sciences (Franklin Lakes, NJ).
MLR. Mixed-leukocyte reaction (MLR) analysis was performed in 96-
well round-bottom plates. Different cell densities of mock-infected or
TB40/e-infected MoLCs were seeded and then cocultured with 8  104
purified allogeneic CD4 T cells that had been purified from peripheral
blood mononuclear cells using a magnetic CD4 T cell enrichment kit
(StemCell Technologies, Vancouver, Canada) for negative selection of
CD4 T cells. MLRs were supplemented with a final concentration of 5 U
of IL-2/ml. T cell proliferation and viability was quantified by trypan blue
cell counting after 6 days of coculture. Different effector/target (E:T) ra-
tios were set up in triplicate.
RESULTS
CD14 monocytes differentiated with TGF- generate a
CD207population of dendritic cells. In order to study the func-
tion ofMoLCs, we isolated CD14 cells from the peripheral blood
of healthy donors and confirmed that they were CD14 and
CD83/CD207 (Fig. 1A). The isolated monocytes were then cul-
tured in X-VIVO 15 medium for 6 days in cytokines that pro-
moted differentiation to either aDCor LC phenotype, resulting in
a similar increase in cell size, granularity, and process formation
when both cell types were visualized by lightmicroscopy (Fig. 1B).
Further characterization was performed alongside CD34 cells
differentiated to an LC phenotype by an analysis of the expression
FIG 1 Differentiation of CD14monocytes with TGF- promotes a Langerhans-like phenotype. (A) Freshly isolatedmonocytes were characterized for CD14,
CD83, andCD207 expression. (B) Lightmicroscopy of freshly isolatedmonocytes ormonocytes cultured for 6 days in IL-4/GM-CSF or IL-4/GM-CSF/TGF-
to promote the formation of aDC (MoDC)- or an LC (MoLC)-like cell type. (C)MoDCs,MoLCs, or Langerhans cells generated fromCD34precursors (CD34
LCs) were analyzed by flow cytometry for class I, class II, CD1a, CD207, and E-Cadherin expression.
HCMV Reactivation in Mature MoLCs
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of a panel of a number of phenotypicmarkers (14, 33). Incubation
of monocytes with TGF- (MoLCs) promoted the formation of a
CD207 population (typically, 50 to 70% of the total population)
upon differentiation that was also evident in CD34 LC cultures
and also consistent with previous observations (14, 48). Further-
more, theMoLCswere predominantly CD1a (87%) and E-Cad-
herin (74%) positive for both markers and exhibited elevated
levels of class I expression compared to classical MoDCs (Fig. 1C)
and, as such, resembled the CD34 LC phenotype rather than the
MoDC phenotype. Taken together, these data are in agreement
with previous observations that the culture of monocytes in DC
differentiation media supplemented with TGF- promotes a
more Langerhans-like phenotype.
MoLCs exhibit maturation dependence for permissive
HCMV infection.Having establishedwe could generate a Langer-
hans-like cell type from CD14 derived monocytes, we next
sought to determine whether these cells were permissive for
HCMV infection. After culture to an immature phenotype,
MoLCs orMoDCswere either left unstimulated or incubatedwith
LPS overnight. Then, the cells were infected at an MOI of 5 with
the myelotropic TB40/e strain or the laboratory strain, Toledo.
Consistent with previous data, staining for IE gene expression
showed that both immature and mature MoDCs were permissive
for HCMV infection with TB40/e (Fig. 2A). In contrast, efficient
infection in MoLCs was only observed after LPS maturation
(Fig. 2B). As expected, both DCs and LCs were poorly infected
with the laboratory strain, Toledo, which exhibits low myelotro-
pism. The immunofluorescence results observed with TB40/e
(Fig. 2A) were consistent with a reverse transcription-PCR (RT-
PCR) analysis that showed substantially lower IE72 gene expres-
sion in immature MoLCs despite the presence of viral genome in
the cells (Fig. 2B).
The block to infection of MoLCs is not due to direct TGF-
signaling. The differences in the permissiveness for infection be-
tween immature MoDCs and MoLCs could be attributable to
more inherent differences in the different cell types or, alterna-
tively, could be associated withmore direct effects of the cytokines
in the medium. The major differential between the two subsets of
cells is the addition of recombinant TGF-. Critical for the forma-
tion of the LC phenotype (25), TGF- is also a pleiotropic cyto-
kine that can modulate the activity of a number of cellular signal-
ing pathways (13). To test whether TGF- signaling was
inherently inhibitory to HCMV infection of MoDCs, CD14
monocytes were cultured in IL-4/GM-CSF for 6 days. Then, 1 h
prior to infection, incubated with TGF- (10 ng/ml) and infected
with HCMV. Staining for IE infection at 24 h postinfection indi-
cated that preincubation with TGF- had no impact on the ability
ofHCMV to infectMoDCs at both low and highMOIs, suggesting
that the long-term effects of promoting differentiation to an
MoLC phenotype were responsible for the differential ability of
HCMV to infect these differentMoDC subsets rather than a direct
inhibition initiated by acute TGF- signaling (Fig. 3).
MoLC are fully permissive, resulting in the production of
infectious progeny. Although our data showed that IE gene ex-
pression could be detected in the infectedmatureMoLCs, we next
sought to determine whether the infection was abortive or re-
sulted in the production of infectious progeny. CD14 cells dif-
ferentiated to MoLCs were subsequently matured with LPS and
then infected with TB40/e at an MOI of 5. Samples of cells were
harvested at 24 and 72 h postinfection and analyzed by Western
blotting for viral gene expression. IE expression was readily de-
tectable by 24 h, and by 72 h the processed form of glycoprotein B
was also detectable (Fig. 4A). Consistent with mature MoLCs be-
ing fully permissive for HCMV, low levels of virus was released
into the supernatant of infected MoLCs up to 12 days postinfec-
FIG 2 A clinical isolate of HCMV infects immature LCs inefficiently. (A)
MoLCs and DCs were infected with TB40/e (columns 1 to 4) or Toledo (col-
umns 5 to 8) before (iDC and iLC) or after (mDC and mLC) LPS stimulation
and analyzed for IE gene expression by immunofluorescencemicroscopy at 24
h postinfection. The percent infection was calculated from four fields per well
from an analysis performed in triplicate. (B) MoLCs and DCs were infected
with TB40/e before (iDC and iLC) or after (mDC and mLC) LPS stimulation
and analyzed by PCR 24 h postinfection for IE72 andGAPDHRNA expression
and the presence of viral genomes.
FIG 3 TGF- does not directly inhibit HCMV infection of immature DCs.
CD14 derived DCs were either not stimulated (columns 1 and 3) or stimu-
lated with TGF- (columns 2 and 4) for 30min prior to HCMV infection. The
cells were then infected at either a low (columns 1 and 2) or a high (columns 3
and 4) MOI and then assayed for infection by immunofluorescence micros-
copy at 24 h postinfection.
Huang et al.
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tion, with production peaking at day 8, and displayed kinetics
similar to those observedwith classicalMoDCs (Fig. 4B). Further-
more, a freeze-thaw analysis of theMoLC cultures indicated that a
significant proportion of infectious virus remained cell bound
(Fig. 4C). The data demonstrate that MoLCs supported the com-
pletion of the lytic life cycle of HCMV.
HCMV infection inhibits the ability of MoLCs to induce al-
logeneic CD4 T cell responses in a mixed leukocyte reaction.
Previously, it has been shown that the infection of mature CD34
derived LCs has profound effects on the immune capacity of those
cells (22). To determine whether MoLCs were similarly targeted
byHCMV,we focused on a functional aspect ofDCbiology. To do
this we performed an MLR. MoLCs mixed with allogeneic CD4
T cells trigger a robust T cell proliferative response, which is con-
sistent with these cells representing potent activators of the im-
mune response (Fig. 5). However, this activation was significantly
diminished after infection with TB40/e (Fig. 5) and was compara-
ble to the phenotype observed for CD34 derived LCs (22). The
most potent effects were observed when the ratio of MoLCs to T
cells was highest and support the hypothesis that infection of
MoLCs functionally impacts on their ability to activate T cells in
vitro. However, it is worth noting that in all our experiments our
virus stocks only gave between 30 and 50% infection, suggesting
that additional mechanisms, as well as direct effects on the in-
fected cell, may be functioning in these assays. For instance, the
fact that the effects were most overt at an E:T ratio of 2:1 suggests
that a concentration-dependent factor derived from infected cells
was contributing, in part, to HCMV immunosuppression of the
MLR reaction. This experiment was repeated four times using
four different donor pairs and, in all experiments, HCMV-in-
fected MoLCs induced poor proliferative CD4 T cell responses
compared to uninfected MoLCs stimulated with LPS.
MoLCs support HCMV reactivation in a maturation-depen-
dent manner. Clearly, the impact of being able to generate LCs
from CD14 precursors will be important for studies of HCMV
latency and reactivation on cells isolated fromhealthy seropositive
donors. Thus, it was important to determine whether these cells
could be used for studies of HCMV reactivation. First, we used an
experimental model of HCMV latency to test this. CD14mono-
cytes were infected with TB40/e. An experimental latent infection
was confirmed by RT-PCR detection of UL138 in the absence of
readily detectable lytic IE gene expression (Fig. 6A), a finding con-
sistent with published data. Subsequently, infected cells were dif-
ferentiated to classical MoDCs or, alternatively, MoLCs and then
analyzed for HCMV reactivation. We have previously observed
that the maturation of either MoDCs or CD34 derived LCs is
concomitant with the reactivation of HCMV. We now show here
that MoLCs also support the reactivation of IE gene expression
upon maturation (Fig. 6B). However, we were struck with the
maturation dependence of MoLCs for efficient reactivation. The
FIG 4 Mature MoLCs support the complete replicative cycle of HCMV. (A) Mature MoLCs were either mock (lanes M) or TB40/e (lanes V) infected and then
analyzed by Western blotting for IE, gB, and GAPDH expression at 24 and 72 h postinfection (hpi). (B and C) Mature CD14 derived DCs (MoDC) or LCs
(MoLC) were infected with TB40/e and then analyzed every 2 days for virus production in the supernatant. Alternatively, at 7 days postinfection both the
supernatant (cell-free) and the lysed cells (cell-associated) were assayed for infectious virus.
FIG 5 Infected mature MoLCs are impaired in their ability to promote T cell
proliferation in a mixed leukocyte reaction. MoLCs were either mock infected
(black) or HCMV infected (gray), followed by incubation, at 72 h postinfec-
tion, with 8 104 T cells at the E:T ratio shown. The T cell proliferation was
assayed for the total cell count from triplicate wells. The results shown are
representative of four independent repeats.
HCMV Reactivation in Mature MoLCs
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addition of IL-6, whichwe have recently shown to promote robust
reactivation of HCMV from immature MoDCs (43), did not trig-
ger readily detectable reactivation of IE gene expression from im-
mature MoLCs in a comparable manner. However, the initiation
and progression of reactivation observed after LPS treatment was
still observed to be IL-6 dependent, with the addition of a neutral-
izing IL-6 antibody significantly impacting the reactivation of IE
gene expression in maturing LCs (Fig. 6B). Furthermore, the ki-
netics of reactivation of IE gene expression in the presence of
different cytokines were also evident in plaque formation and the
subsequent production of infectious progeny in cocultures
(Fig. 6C andD).Microscopic analysis of the fibroblastmonolayers
exhibited minimal plaque formation at 10 days after coculture
(and at 15 days after reactivation) except in the LPS-stimulated
MoLC cultures and, more evidently, in mature MoLCs (LPS) co-
stimulated with IL-6 (Fig. 6C). Furthermore, the observed cyto-
pathic effect correlated with the levels of infectious virus produc-
tion detectable in the cocultures (Fig. 6D).
Interestingly, we also observed the same effects in our studies
of CD34 derived LC reactivation. Akin to MoLCs, reactivation
was crucially dependent on maturation (LPS), since immature
CD34 derived LCs did not respond to the IL-6 alone (Fig. 7A,
lanes 3 and 5). However, IL-6 was observed to be a crucial com-
ponent of LPS-induced reactivation (Fig. 7B), and the addition of
recombinant IL-6 was also observed to have the same enhancing
effect on reactivation from mature CD34 derived LCs (Fig. 7A,
lanes 4 and 6).
MoLCs support reactivation of naturally latent HCMV from
healthy seropositives. Finally, we have previously observed that
the isolation of CD34 cells from healthy seropositive donors and
subsequent differentiation to mature LCs promotes the reacti-
vation of HCMV (45). We show here that MoLCs also support
the reactivation of naturally latent HCMV after stimulation
with LPS (Fig. 8A). Furthermore, consistent with our data de-
rived from experimental latency analyses, we also observed that
IL-6 signaling is an important factor for efficient reactivation of
HCMV in maturing CD14 derived and CD34 derived LCs
and that the effects of IL-6 are only observed in mature LC
cultures (Fig. 8) in contrast to previous observations with im-
mature MoDCs (43).
DISCUSSION
A number of laboratories have used experimental latent infection
of primary cells to address the mechanisms that govern latency
and reactivation of HCMV (16, 17, 19, 20, 37, 43, 44, 55, 64). The
use of these models has made it possible to perform large-scale
screen based experiments in an attempt to characterize global
events that occur during the phases of latent infection (8, 17, 41,
55). Although such exploratory experimentation on naturally la-
tent HCMV is rendered inherently difficult by the low frequency
of genome-positive cells in themononuclear compartment (54), it
remains important to confirm findings in experimental systems
by studying the natural state of latent HCMV.
Amajor site of natural HCMV latency in the host is the CD34
cell compartment that populates the bonemarrow (34, 53) and, as
such, the use of this tissue has been extensive in the establishment
of experimental models of HCMV latency (17, 44, 55, 64). How-
ever, in this reportwe sought to analyze the biology ofMoLCswith
regard to HCMV and, in particular, how these cells compared to
both classicalMoDCs and CD34 LCs. In our experimental mod-
FIG 6 Efficient reactivation of HCMV from MoLCs is maturation dependent and enhanced by IL-6. (A) CD14 monocytes TB40/e (lanes 1 and 2) or mock
(lanes 3 and 4) infected were analyzed for RNA expression at 3 days postinfection. RNA with () or without () prior RT was amplified in UL138, IE72, and
actin-specific PCRs. For the IE72 PCR, anHCMVDNAPCR-positive control was included to confirm that the PCR had worked (lane 5). (B) RNA isolated from
immatureMoLCs either mock treated (lane 1) or treated with IL-6 (lane 2), IL-8 (lane 3), LPS (lane 4), LPS plus neutralizing IL-6 antibody (lane 5), or LPS plus
neutralizing IL-8 antibody (lane 6) was () or was not () subjected to RT and then amplified in an IE72 or actin PCR. (C and D)MoLCs were cocultured with
fibroblasts to assay HCMV reactivation. After 10 days, the cultures were analyzed for evidence of plaque formation (C) and HCMV reactivation by inoculating
fresh monolayers of fibroblasts with 50 l of the supernatant and staining for IE gene expression 24 h postinfection as an indicator of infectious virus in the
supernatant (D).
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els of HCMV latency, the differentiation of CD34 cells tomature
LangerhansDCs—ahighly specialized population ofDCs resident
in the periphery—is important for triggering HCMV reactivation
(44, 46). However, since we increasingly wish to understand the
interplay between immunology, inflammation, and HCMV reac-
tivation, it is clearly important that we have access to material
from fully characterized healthy donors from an immunological
viewpoint. This is illustrated by the current debate regarding the
contribution of HCMV to the progression of atherosclerosis (1, 7,
12, 18). One postulated explanation for the discrepancies has been
attributed to the ability of different individuals to control HCMV
infection and disease—and thus a function of the donor-specific
immune responses observed in patients (63). Coupled with donor
specific immune response outcomes is the observation that the
reactivation of HCMV is triggered by cytokines produced by allo-
geneically stimulated T lymphocytes (56); it thus becomes impor-
tant to consider the impact of immune mismatching. As such,
experiments using a wholly autologous culture system with do-
nors fully characterized from an immunological viewpoint allows
us to appreciate these important caveats when studying normal
immunological responses to latent and reactivating HCMV in
healthy individuals. Consequently, we sought to address whether
MoLCs were functionally akin to MoDCs or CD34 derived LCs
in the context of HCMVbiology and how these different cell types
responded to a proreactivation stimulus.
In the present study, we show that we can generate LCs from
monocyte precursors that have strong functional similarities to
CD34 derived LCs with regard to HCMV biology, supporting
the premise that LCs exhibit fundamental differences from DCs
regarding HCMV biology. CD14 monocytes isolated from pe-
ripheral blood can be differentiated in the presence of TGF- into
LC-like DCs evidenced by the induction of CD207, E-Cadherin,
and CD1a surface expression. Furthermore, we show that lytic
infection of these cells is dependent on differentiation to amature
phenotype and, once matured, these cells are fully permissive for
the complete replication cycle of HCMV, resulting in the produc-
tion of progeny virus. Consistent with the expression of the com-
plete set of viral genes, a profound effect on the immunostimula-
tory capacity of the infected MoLCs was observed.
A crucial aspect for our own ongoing studies is the ability of
these cells to carry and reactivate HCMV genome in experimental
latency. The subtle differences between the LC subtype and other
monocyte/DC experimentalmodels (19, 42) observedwith regard
to their reactivation phenotype could be an important indicator of
the fundamental processes involved in HCMV reactivation upon
myeloid differentiation through different lineages, assuming that
these in vitro-generated cells truly reflect the in vivo populations of
myeloid DCs. Furthermore, such HCMV-specific effects could
also provide scope for further investigation of the functional dif-
ferences evident in myeloid DC subsets. The differential response
FIG 7 Efficient reactivation of HCMV from CD34 derived LCs is matu-
ration dependent and is responsive to IL-6. (A) CD34 derived immature
LCs either mock treated (column 1) or cultured with LPS (column 2), IL-6
at 5 to 50 ng/ml (columns 3 and 5), or LPS plus IL-6 at 5 to 50 ng/ml
(columns 4 and 6) and then analyzed for IE and actin gene expression by
real-time quantitative RT-PCR. The results are expressed as the fold change
in IE gene expression compared to LPS alone. (B) CD34 derived imma-
ture LCs were either mock treated (column 1) or incubated with LPS (col-
umn 2), LPS plus neutralizing IL-6 antibody (IL6; columns 3, 5, and 7), or
isotype-matched control (IgG; columns 4, 6, and 8) and analyzed by quan-
titative RT-PCR for IE and actin gene expression. Reactivation is expressed
as a function of LPS alone (100%).
FIG 8 Reactivation of naturally latent HCMV is observed in LCs derived from
CD14 and CD34 progenitor cells. (A) CD14 cells isolated from CMV-
seropositive and -seronegative donors were differentiated to immature LCs
and then either mock treated (lane 1) or incubated with LPS (lane 2), LPS plus
50 ng of IL-8/ml (lane 3), or LPS plus 50 ng of IL-6/ml (lane 4) and analyzed for
IE and actin gene expression by RT-PCR (n  4). (B) CD34 cells isolated
from CMV-seropositive and -seronegative donors were differentiated to im-
mature LCs and then either mock treated (lane 1) or incubated with LPS (lane
2), LPS plus 1 g of nIL6ab/ml (lane 3), LPS plus 1 g of nIL8ab/ml (lane 4),
LPS plus 50 ng of IL-6/ml (lane 5), or LPS plus 50 ng of IL-8/ml (lane 6) and
then analyzed for IE and actin gene expression by RT-PCR (n 4).
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ofDC subsets toHCMV is not pathogen specific; culture ofmono-
cytes in Th2-mediated inflammatory conditions generates mixed
populations of DCs that respond differently to inflammatory
stimuli, and thus not all DCs are homogeneous in their normal
biology (3). Pertinent to our current studies is the question of why
the effects of IL-6 on reactivation are only observed on mature
CD34 derived or MoLCs, whereas immature MoDCs, or mono-
cytes cultured long term in a cytokine cocktail to promote survival
(19), reactivate HCMV in response to IL-6 as efficiently as do
matureMoDCs (43). One possibility is that immature LCs are less
responsive to proinflammatory conditions in general. It has been
argued that tolerization of LCs could be an important event to
ensure that unnecessary inflammatory immune responses do not
occur in the periphery (10). Indeed, it has recently been shown
that LCs are less efficient at promoting the development of the
effector/memory CD4 T cell phenotype (51). In the context of
HCMV, it has always been proposed that it is a paradox that reac-
tivation occurs in a cell type (i.e., a DC) that represents the arche-
typal professional antigen-presenting cell. However, in the con-
text of a less-than-robust immune response in the LC subset,
reactivation in the periphery could represent an important mech-
anism that facilitates horizontal dissemination prior to efficient
immune surveillance.
Clearly, there is a direct correlation between the permissiveness
of differentiatedmyeloid cells for HCMV infection and the capac-
ity to drive reactivation in these cells upon delivery of inflamma-
tory signals. The triggering of efficient reactivation with inflam-
matory mediators appears to correlate precisely with the
permissiveness of each of the cell types involved for HCMV lytic
infection. Indeed, it is possible that we identified thesematuration
specific events in LCs that are important for reactivation because
all our primary cell culture was performed under serum-free con-
ditions. For instance, the culture of CD14 cells to DCs has been
shown to produce a more heterogeneous differentiated myeloid
cell phenotype (including macrophage-like cells) in the presence
of serum contaminants that could confound analyses attempting
to study HCMV reactivation in particular subsets of cells (32, 38).
It will be interesting to determine the proteomic differences that
exist between immature DCs and LCs that promotes reactivation
of HCMV in one subset but not the other in response to inflam-
matory signaling. It is also anticipated that elucidation of the na-
ture of these inflammatory responsive elements may also impact
on our further understanding of the response of different myeloid
DC subsets to environmental cues.
We have established here that CD14 and CD34 derived LCs
have a similar reactivation phenotype that subtly differs from
more classical CD14 derived DCs. Because we can observe dif-
ferences between MoLCs and MoDCs, it may be possible to take
the same starting cell phenotype, from the same donor, and then
differentiate it down two independent pathways that exhibit sub-
tly different phenotypes to perform proteome analyses without
the added caveats of donor to donor variability that could occur
using unmatched CD34 and CD14 cells. As such, one would
predict that a greater similarity in proteome profilesmaymake the
identification of the differences responsible for their phenotype
with regard to HCMV biology easier to elucidate. Ultimately,
study of the molecular kinetics of reactivation in different cell
types could provide new clues regarding the differential regulation
of mechanisms controlling HCMV reactivation.
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